Case Information
*1 Before HULL, JORDAN, and JULIE CARNES, Circuit Judges.
PER CURIAM:
In this direct appeal, Azubueze Ikejiani appeals his conviction and 11-month sentence imposed after pleading guilty to one count of holding misbranded prescription drugs for sale in interstate commerce, in violation of 21 U.S.C. § 331(k). Following a careful review of the record and briefs, we affirm.
I. BACKGROUND
A. Offense Conduct
We recount the facts from Ikejiani’s factual proffer, his guilty plea colloquy, his sentencing hearing, and the presentence investigation report (“PSI”). Ikejiani is a licensed pharmacist. In 2006, Ikejiani, through his company Kanec (USA), Inc., manufactured and distributed approximately 240,000 capsules of a product called “XOX For Men” (“XOX”) without a prescription. In March 2007, Canadian health authorities issued a warning and recall of XOX because it contained tadalafil, the active ingredient in the prescription erectile dysfunction drug Cialis. Ikejiani admitted to Food and Drug Administration (“FDA”) investigators that he had manufactured and distributed XOX, as well as another product called “Stud Capsule for Men” (“Stud”), but claimed that he had discontinued manufacturing these items by April 2007.
In January 2010, an individual purchased some Stud capsules manufactured and distributed by Ikejiani, ingested one, and suffered an adverse reaction. On February 5, 2010, that individual reported the adverse reaction to FDA agents and provided them with his remaining Stud capsules. Testing revealed that the Stud capsules contained twice the maximum prescription dosage of sildenafil citrate, the active ingredient in the prescription erectile dysfunction drug Viagra.
In March 2010, the FDA conducted another investigation of Ikejiani. Ikejiani admitted that he manufactured and distributed Stud using raw materials imported from India. While Ikejiani claimed that he did not know that Stud contained active pharmaceutical ingredients, emails recovered pursuant to a search warrant revealed that Ikejiani specifically ordered sildenafil citrate by name in large quantities for various shipments. FDA investigators advised Ikejiani to stop selling products that contained sildenafil citrate and tadalafil, and Ikejiani assured them that he would no longer sell or distribute such products.
Nevertheless, in December 2010, the FDA discovered that Ikejiani continued to manufacture and distribute a product called “Nite Rider,” which contained sildenafil citrate. On January 7, 2011, FDA investigators interviewed Ikejiani again. Ikejiani admitted to the continuing manufacture and sale of Nite Rider, but denied putting any active pharmaceutical ingredients in his products. Ultimately, investigators recovered invoices proving that, between 2007 and 2010, Ikejiani sold $413,428 worth of products containing sildenafil citrate and tadalafil to wholesale customers without a prescription.
B. Criminal Information and Guilty Plea
On September 19, 2014, the government charged Ikejiani by criminal information with one count of holding misbranded drugs for sale in interstate commerce with intent to defraud, in violation of 21 U.S.C. § 331(k). Ikejiani initially pleaded not guilty, but later pleaded guilty without the benefit of a plea agreement.
At a November 7, 2014 change of plea hearing, the district court placed Ikejiani under oath and informed him that he could be prosecuted for perjury if he made any false statements. Ikejiani testified that he understood the purpose of the hearing, read the criminal information in its entirety, understood the charges against him him, discussed the evidence with his attorney, and understood everything his attorney had told him about the case. The court then read the criminal information aloud, and Ikejiani confirmed that he understood the charge against him.
Ikejiani also confirmed that he read the written factual proffer in its entirety and signed it. Moreover, the factual proffer was explained by Ikejiani’s attorney, Ikejiani understood everything in it, and Ikejiani confirmed that all of the facts set forth therein were true and accurate. The district court then informed Ikejiani of the consequences of pleading guilty, including the forfeiture of several rights. The district court ultimately accepted Ikejiani’s guilty plea and adjudicated him guilty of the charged offense.
C. Sentencing
The PSI recommended a base offense level of six, pursuant to U.S.S.G. § 2N2.1(c)(1). The PSI added to that base offense level: (1) a 14-level increase because the loss value was more than $400,000 but less than $1,000,000, § 2B1.1(b)(1)(H); (2) a two-level increase because the offense involved ten or more victims, § 2B1.1(b)(2)(A); (3) a two-level increase because the offense involved the conscious risk of death or serious bodily injury, § 2B1.1(b)(15)(A); (4) a two-level increase because Ikejiani abused a position of trust or used a special skill in the commission or concealment of the offense, § 3B1.3; and (5) a three- level reduction for acceptance of responsibility and cooperation with authorities, § 3E1.1(a) and (b).
Ikejiani’s total adjusted offense level was 23. Based on this total offense level and a criminal history category of I, Ikejiani’s advisory guidelines range was 46 to 57 months’ imprisonment. However, because the statutory maximum term of imprisonment was 1 year, the advisory guidelines range became 12 months, pursuant to U.S.S.G. § 5G1.1(a).
At sentencing, Ikejiani’s counsel requested a sentence that did not include a term of confinement. In support of his request, Ikejiani’s counsel noted that he accepted full responsibility for his crime and was fully cooperative with the government. Ikejiani’s counsel further noted that nobody suffered great bodily harm from consuming Ikejiani’s products, but did not explicitly object to the enhancements in the PSI.
Ikejiani’s counsel also argued that Ikejiani’s personal history and background weighed in favor of non-confinement. Specifically, Ikejiani was forced into military service as a teenager during a Nigerian civil war, had been law abiding for the four or five years after the offense conduct, did not pose a risk of harm to the public, was not a violent individual, and was the sole provider for his large family.
Ikejiani personally addressed the court and apologized for his actions. The district court asked questions regarding the health risk that Ikejiani’s misbranded products posed, and Ikejiani acknowledged the risk and apologized. Ikejiani then informed the court that he suffered from benign prostate hyperplasia, supported his children in college, and volunteered for disaster relief efforts.
The government requested the maximum 12-months’ imprisonment sentence, emphasizing the seriousness of Ikejiani’s offense, his specialized knowledge, and his repeated fraudulent behavior.
The district court adopted the factual findings and advisory guidelines calculations contained in the PSI, and stated that it had considered the facts and circumstances surrounding the offense, the statements of the parties, the applicable advisory guidelines range, and the statutory factors set forth at 18 U.S.C.
§ 3553(a). The district court sentenced Ikejiani to serve 11 months’ imprisonment—a sentence one month below Ikejiani’s advisory guidelines range—followed by one year of supervised release. The district court also imposed an $11,000 fine.
After pronouncement of his sentence, Ikejiani asked once again for a non- custodial sentence, but the court declined to alter the sentence. Ikejiani had no objections to the manner in which the sentence was imposed. The district court stated that the 11-month sentence promoted respect for the law, deterred future criminal conduct, and provided just punishment.
II. DISCUSSION
A. Ikejiani’s “Dispensed” Argument
Defendant Ikejiani argues for the first time on appeal that his guilty plea
must be vacated because, as a wholesaler, he is innocent of the charged conduct.
Ikejiani’s argument turns on the use of the word “dispensed” in 21 U.S.C.
§ 353(b)(1), which, he argues, is limited to distribution to the end user by virtue of
the definition of “dispensed” given in 21 U.S.C. § 802(10).
[1]
We apply plain error review when a defendant failed to raise an argument in
the district court. United States v. Vandergrift,
Federal law prohibits “the doing of any . . . act with respect to. . . [a] drug . .
. if such act is done while such [drug] is held for sale (whether or not the first sale) after shipment in interstate commerce and results in such article being adulterated or misbranded.” 21 U.S.C. § 331(k). “The act of dispensing a drug [without a prescription] shall be deemed to be an act which results in the drug being misbranded while held for sale.” Id. § 353(b)(1).
In the context of a 21 U.S.C. § 331(k) prosecution, this Court’s predecessor
held that the term “dispensing,” as used in § 353(b)(1), applies to all sales,
including wholesale sales, and not merely to sales to end users. United States v.
De Freese,
prior binding precedent until it is overruled by this Court sitting en banc or by the
United States Supreme Court. United States v. Vega-Castillo,
Here, the district court did not plainly err by accepting Ikejiani’s guilty plea.
This Court’s predecessor rejected Ikejiani’s argument long ago in a precedential
decision that has not been overruled. De Freese,
former Fifth Circuit held that “the fact that the crime . . . is wholesale, instead of
retail, gives [the defendant] no special claim to immunity.” Id. at 737. We are
bound to follow this precedent. Vega-Castillo,
B. Guilty Plea and Rule 11
Defendant Ikejiani next argues for the first time on appeal that the district
court did not conduct a proper guilty plea colloquy under Rule 11 of the Federal
Rules of Criminal Procedure. Specifically, the district court (1) failed to properly
inform Ikejiani of the nature of the charges to which he pleaded guilty, and (2)
accepted Ikejiani’s guilty plea without a proper factual basis supporting the charge.
We review the issue of a violation of Rule 11 for plain error when it was not
raised before the district court. United States v. James,
Cir. 2000).
Before accepting a guilty plea, a district court must ensure that the defendant
understands the nature of the charge. See Fed. R. Crim. P. 11; James, 210 F.3d at
1344. There is no one mechanical or precise juncture to which a district judge
must conform in advising a defendant of the nature of the charges to which he is
pleading guilty. James,
A district court must also determine that there is a factual basis for the plea
before accepting it. Fed. R. Crim. P. 11(b)(3); United States v. Frye, 402 F.3d
1123, 1128 (11th Cir. 2005) The purpose of this requirement is to protect a
defendant who mistakenly believes that his conduct constitutes the criminal
offense to which he is pleading. Frye,
Here, the district court did not plainly err while conducting Ikejiani’s guilty
plea colloquy. The district court recited verbatim the single count of the criminal
information (to which Ikejiani pled guilty) to Ikejiani in open court. Ikejiani stated
that he fully understood the charge against him and had no questions for the court.
This process sufficiently ensured that Ikejiani understood the nature of the charge
against him. James,
Additionally, the district court was presented with a sufficient factual basis
for accepting Ikejiani’s guilty plea. Specifically, the district court considered
Ikejiani’s signed factual proffer and ensured that the facts set forth therein were
truthful and accurate. The factual proffer provided that on several occasions
Ikejiani dispensed mislabeled products containing the drugs sildenafil citrate and
tadalafil into interstate commerce without a prescription.
[2]
Accordingly, the district
court was presented with evidence from which it could reasonably find that
Ikejiani was guilty. Frye,
In sum, the district court did not plainly err in following the requirements of Rule 11.
C. Sentencing Enhancements
Defendant Ikejiani next argues for the first time on appeal that the enhancements the district court applied to his Sentencing Guidelines calculations violated his Sixth Amendment right to a jury trial and his Fifth Amendment right to a grand jury indictment. He further argues for the first time on appeal that there was no evidence to support his victim number and bodily injury enhancements under §§ 2B1.1(b)(2)(A) and 2B1.1(b)(15)(A).
1. Constitutional Claims
Sentencing enhancements that do not increase the statutory minimum or
maximum term of imprisonment that a defendant faces need not be charged in an
indictment and submitted to a jury. See United States v. King,
Here, the district court’s ultimate guidelines calculations neither raised Ikejiani’s sentence above the one-year statutory maximum, nor raised any applicable statutory minimum. Thus, the district court was not required to submit the facts underlying its guidelines calculations to a jury. See King, 751 F.3d at 1278-79. Accordingly, the district court did not err, much less plainly err, as to Ikejiani’s constitutional arguments on appeal.
2. Evidentiary Claims
As noted above, error is not plain unless it affects a defendant’s substantial
rights. Turner,
Here, we need not determine whether there was a sufficient evidentiary basis for each of the challenged enhancements, as the district court’s error, if any, did not affect Ikejiani’s substantial rights. Specifically, if the district court did not apply the challenged enhancements, then Ikejiani’s total offense level would have decreased by four levels, to 19. With a total offense level of 19 and a criminal history category of I, Ikejiani’s advisory guidelines range would have been 30 to 37 months. However, due to the one-year statutory maximum under 21 U.S.C. § 333(a)(1), and pursuant to U.S.S.G. § 5G1.1(a), Ikejiani’s advisory guidelines range would have still been 12 months.
Accordingly, even if we were to hypothetically conclude that the district
court erred by adopting the challenged enhancements, it did not plainly err, as there
is no reasonable probability that, but for the error, Ikejiani’s sentence would have
been different. Rodriguez,
D. Substantive Reasonableness
Defendant Ikejiani next argues that his sentence is substantively unreasonable because the district court did not assign enough weight to his mitigation evidence.
We review the reasonableness of a sentence for abuse of discretion. United
States v. Cubero,
Here, Ikejiani’s 11-month custodial sentence was substantively reasonable.
The district court listened to the parties’ arguments as to the appropriate sentence
and stated that it had considered those arguments, the PSI, and the § 3553(a)
factors. We cannot say that the district court abused its discretion in finding that a
sentence of incarceration was necessary to promote respect for the law, deter future
criminal conduct, and provide just punishment under the particular facts of this
case. While Ikejiani emphasized his medical issues, family obligations, and
humanitarianism, the district court attached great weight to the danger Ikejiani’s
crime posed to the public. This was an appropriate exercise of discretion, and this
Court does not reweigh the § 3553(a) factors. See Clay,
In sum, Ikejiani has failed to show that the district court abused its discretion by deciding that a sentence of 11 months’ imprisonment, rather than a non- custodial sentence, was appropriate in light of the § 3553(a) factors.
E. Ineffective Assistance of Counsel
Finally, defendant Ikejiani asserts that his trial counsel rendered ineffective assistance of counsel by failing to inform him that he did not “dispense” the drugs within the meaning of the charged criminal statute, thus allowing him to plead guilty to a crime he did not commit. Ikejiani further asserts that his trial counsel failed to object to the PSI and failed to challenge the district court’s sentencing enhancements. He argues that these failures, individually and in combination, caused undue prejudice.
Generally, the record is not sufficiently developed on direct appeal to allow
meaningful review of ineffective assistance claims. See United States v. Merrill,
Here, we decline to consider Ikejiani’s ineffective assistance claims on direct appeal, as the district court did not have the opportunity to develop a record on the issue. See id.
III. CONCLUSION
For the foregoing reasons, we affirm defendant Ikejiani’s conviction and sentence.
AFFIRMED.
Notes
[1] 21 U.S.C. § 802 provides: “As used in this subchapter . . . [t]he term dispense means to deliver a controlled substance to an ultimate user.” 21 U.S.C. § 802(10) (emphasis added). Section 802 appears in Title 21, Chapter 13, Subchapter I, while the charged offense appears in Title 21, Chapter 9, Subchapter III. Accordingly, it is not clear how the definition of “dispense” in § 802, which is expressly limited to its use in Chapter 13, Subchapter I, has any bearing on the construction and interpretation of the term “dispensing” as used in § 353. In any event, as discussed below, Ikejiani’s argument is squarely foreclosed by binding precedent.
[2] Ikejiani argues that the factual proffer was insufficient by reasserting his argument that,
as a wholesaler, he did not “dispense” the drugs as charged in the criminal information.
However, as described above, wholesale distribution constitutes “dispensing” for the purposes of
charged offense. See De Freese,
[3] The § 3553(a) factors include: (1) the nature and circumstances of the offense and the history and characteristics of the defendant; (2) the need to reflect the seriousness of the offense, to promote respect for the law, and to provide just punishment for the offense; (3) the need for deterrence; (4) the need to protect the public; (5) the need to provide the defendant with needed educational or vocational training or medical care; (6) the kinds of sentences available; (7) the Sentencing Guidelines range; (8) pertinent policy statements of the Sentencing Commission; (9) the need to avoid unwarranted sentencing disparities; and (10) the need to provide restitution to victims. 18 U.S.C. § 3553(a).
